Status:
COMPLETED
A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies
Lead Sponsor:
Verastem, Inc.
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Phase 1 safety, pharmacokinetics, and pharmacodynamics trial of the focal adhesion kinase (FAK) inhibitor PF-04554878 in patients with advanced non-hematologic malignancies, including patients with ma...
Eligibility Criteria
Inclusion
- Patients with advanced non-hematologic malignancies.
- Adequate organ function, including bilirubin less than 1.5 x ULN, and ECOG (Eastern Cooperative Oncology Group) performance status of 0-2.
Exclusion
- Clinically significant gastrointestinal abnormalities, requirement for systemic anticoagulants or potent CYP 2C8 inhibitors, and history of clinically significant cardiac or pulmonary disorders
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT00787033
Start Date
December 1 2008
End Date
February 1 2012
Last Update
January 25 2017
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Boston, Massachusetts, United States, 02114
2
Pfizer Investigational Site
Boston, Massachusetts, United States, 02115
3
Pfizer Investigational Site
Boston, Massachusetts, United States, 02215
4
Pfizer Investigational Site
Nashville, Tennessee, United States, 37203